(MBRX)
0.00
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.00
0.00 (0.00%)
Moleculin Biotech, Inc., kechki bosqichdagi farmatsevtika rivojlanish kompaniyasi, o'smalar va viruslarni davolash uchun terapevtik nomzodlarni ishlab chiqish bilan shug'ullanadi. Uning asosiy dori nomzodi Annamycin, antitsiklin bo'lib, u qaytalanuvchi yoki refrakter o'tkir miyeloid leykemiya va yumshoq to'qimalar sarkomasi o'pka metastazlarini davolash uchun klinik bosqichda. Kompaniya, shuningdek, WP1066 portfelini ishlab chiqmoqda, jumladan WP1066, WP1193 va WP1220, ular miya o'smalari va oshqozon osti bezi va boshqa saraton kasalliklari uchun fosforlangan signal transduser va transkriptsiya faollashtiruvchisini inhibe qilish uchun mo'ljallangan immunitet/transkripsion modulyatorlardir. Bundan tashqari, u WP1122 portfelini ishlab chiqmoqda, masalan, WP1122, WP1096 va WP1097, ular o'smalarning energiya ta'minotini uzadigan 2-deoksi-D-glyukoza kabi glikoliz inhibitorlaridan foydalanishni maqsad qilgan. Kompaniya 2015 yilda tashkil etilgan va Xyuston, Texasda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Donald H. Picker Ph.D. | Chief Scientific Officer |
| Dr. John Paul Waymack M.D., Sc.D. | Senior Chief Medical Officer |
| Dr. Waldemar Priebe Ph.D. | Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board |
| Mr. Jonathan P. Foster CPA | Executive VP & CFO |
| Mr. Walter V. Klemp | Co-Founder, Chairman, President & CEO |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-19 | 8-K | mbrx20260318_8k.htm |
| 2026-03-18 | 10-K | mbrx20251231_10k.htm |
| 2026-03-09 | DEF 14A | mbrx20260304_def14a.htm |
| 2026-01-20 | 8-K | mbrx20260113_8k.htm |
| 2026-01-13 | 8-K | mbrx20260110c_8k.htm |
| 2026-01-12 | 8-K | mbrx20260110_8k.htm |
| 2026-01-07 | 8-K | mbrx20260106_8k.htm |
| 2026-01-02 | DEF 14A | mbrx20251229_def14a.htm |
| 2025-12-23 | S-3 | mbrx20251217_s3.htm |
| 2025-12-22 | PRER14A | mbrx-20251231.htm |